...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer

The TNBC trial is now recruiting in at least four locations in the US:

https://clinicaltrials.gov/ct2/show/NCT03901469

And based on this tweet and this tweet, it sounds like Europe may be in on this too!

https://twitter.com/aftimosp/status/1166650663125864448?s=20

https://twitter.com/aftimosp/status/1166652012538335232?s=20

BearDownAZ

 

Share
New Message
Please login to post a reply